CVRx Inc. (CVRX) just launched what might be one of the biggest bets in heart device history. The company announced Thursday that it's kicking off the BENEFIT-HF clinical trial, a massive randomized study involving 2,500 heart failure patients that could fundamentally reshape its business if things go well.

Here's what makes this interesting: the trial has CMS Category B IDE coverage, which is a fancy way of saying Medicare will pay for it. That's important not just because clinical trials are expensive, but because it opens up a much broader patient population for the study.

The star of the show is Barostim, an implantable device that's already FDA-approved and commercially available in both the U.S. and Europe. It works by sending electrical signals to baroreceptors (sensory neurons that monitor blood pressure) on the carotid artery. This increases baroreflex signaling, which helps rebalance the autonomic nervous system and improves heart failure symptoms. Think of it as a pacemaker for your nervous system rather than your heart directly.

Barostim got FDA approval back in 2019 after earning a spot in the FDA's Breakthrough Devices Program. Now CVRx wants to prove it works in a much larger slice of the heart failure population.

The Numbers Tell an Interesting Story

The trial's primary endpoint will track a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026, and if successful, the study could expand Barostim's indicated patient population by roughly three times.

William Blair analysts are clearly excited about this. They wrote Friday that if successful, "this trial would roughly triple the company's TAM." They also noted that the scale and rigor of the trial should "turn heads in the cardiology community, ultimately drawing more attention to Barostim and likely providing a tailwind to procedures overall."

There's also a revenue angle here that analyst Brandon Vazquez previously highlighted. With two-thirds of the 2,500 patients set to receive Barostim therapy (around 1,650 devices) throughout the trial, and assuming a $30,000 price tag per device, that represents an incremental $50 million in top-line revenue just from the trial itself.

William Blair maintains an Outperform rating on CVRx.

Price Action: CVRx shares jumped 15.93% to $7.60 at the time of publication on Friday.